Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 27Magnetic Resonance Spectroscopy 23Cyclophosphamide 16Biopsy 16Doxorubicin 13pembrolizumab 11Temozolomide 11X-Rays 10Radiation 10atezolizumab 8Radiotherapy 8Irinotecan 8Phantoms, Imaging 7Nivolumab 7fludarabine 6Vincristine 6Immunoglobulin G 6Etoposide 6Bevacizumab 6liposomal doxorubicin 5cemiplimab 5cabozantinib 5Sirolimus 5Ifosfamide 5Gemcitabine 5Disulfides 5palbociclib 4olaparib 4fludarabine phosphate 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leyk × Sarcoma × 30 days × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡